Skip to search formSkip to main contentSkip to account menu

vinorelbine

Known as: Vinorelbin, Dihydroxydeoxynorvinkaleukoblastine, C'-Norvincaleukoblastine, 3',4'-didehydro-4'-deoxy- 
A semisynthetic vinca alkaloid. Vinorelbine binds to tubulin and prevents formation of the mitotic spindle, resulting in the arrest of tumor cell… 
National Institutes of Health

Related topics

Related topics

23 relations

Broader (3)

Antineoplastic Agents, PhytogenicVinblastineanhydrovinblastine
Drug AllergyHodgkin DiseaseMammary NeoplasmsMicrotubule Process

Narrower (3)

KW 2307NavelbineVinorelbine tartrate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
PURPOSE Docetaxel has not been compared with vinorelbine as adjuvant treatment of early breast cancer. Efficacy and long-term… 
Review
2008
Review
2008
Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?
Highly Cited
2007
Highly Cited
2007
Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer
Purpose: To assess pathologic complete response (pCR), clinical response, feasibility, safety, and potential predictors of… 
Highly Cited
2002
Highly Cited
2002
Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer…
PURPOSE To evaluate new drugs in combination with cisplatin in unresectable stage III non-small-cell lung cancer, Cancer and… 
Highly Cited
2001
Highly Cited
2001
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.
PURPOSE To determine the response rate and toxicity profile of trastuzumab administered concurrently with weekly vinorelbine in… 
Highly Cited
2000
Highly Cited
2000
Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer.
PURPOSE To evaluate whether the addition of gemcitabine (G) to vinorelbine (V) improves survival and quality of life (QoL) among… 
Highly Cited
2000
Highly Cited
2000
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
The blockade of epidermal growth factor receptor (EGFR) function with monoclonal antibodies has major antiproliferative effects… 
Highly Cited
1994
Highly Cited
1994
Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612…
PURPOSE We designed a prospective randomized trial to compare vinorelbine and cisplatin (NVB-P) with vindesine and cisplatin (VDS… 
Review
1994
Review
1994
Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.
Paclitaxel is a new anticancer agent with a novel mechanism of action. It promotes polymerisation of tubulin dimers to form… 
Highly Cited
1991
Highly Cited
1991
A Phase II Study of Navelbine (Vinorelbine) in the Treatment of Non‐Small‐Cell Lung Cancer
Navelbine (vinorelbine, NVB) is the first semisynthetic 5'-nor-vinca-alkaloid selected for clinical trial. NVB has been shown to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)